Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
New Therapy for Chronic Graft-Vs-Host Disease: Axatilimab
Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at ...
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease ...
Axatilimab in Chronic Graft-versus-Host Disease | New England Journal ...
A Review of Axatilimab in Steroid Refractory Chronic Graft versus Host ...
New Therapy for Chronic Graft-Vs-Host Disease: Axatilimab | Pharmacy Times
Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody ...
Efficacy of Axatilimab in the Management of Chronic Graft-Versus-Host ...
Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with ...
Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy ...
Axatilimab (SNDX-6352) | Anti-CSF-1R Antibody | MedChemExpress
FDA Approval Summary: Axatilimab for Adult and Pediatric Patients ...
Exposure‐Response Relationships for Axatilimab in Patients with Chronic ...
FDA approves axatilimab for the treatment of chronic graft-versus-host ...
Study Comparing Axatilimab to Best Available Therapy for Patients with ...
Safety Analysis of Axatilimab in Patients with Chronic Graft-Versus ...
Axatilimab Immunogenicity and Clinical Relevance in Patients with ...
Axatilimab
Axatilimab in combination with ruxolitinib in patients with newly ...
FDA Approves Axatilimab for Chronic Graft-vs-Host Disease
Figure 1 from Axatilimab for Chronic Graft-Versus-Host Disease After ...
Axatilimab meets primary outcome in phase 2 chronic graft versus host ...
AGAVE-201 Study - FDA Approval of Axatilimab for Chronic Graft-versus ...
Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results (NASDAQ ...
Axatilimab induces ‘robust responses’ in chronic GVHD
Axatilimab Zur Behandlung Der Rezidivierenden Chronischen Graft-versus ...
Incyte Reports the US FDA’s Acceptance of BLA for Axatilimab with ...
Safety and Efficacy of Axatilimab in Patients with Chronic Graft-Versus ...
Axatilimab in Chronic Graft-Versus-Host Disease AGAVE 201 Results ...
Mehdi Hamadani: Efficacy of axatilimab in chronic graft-versus-host ...
Axatilimab Continues to Improve Outcomes in Chronic GVHD
A Comprehensive Analysis of Axatilimab in Patients with Chronic Graft ...
Axatilimab Shows Robust Activity in Chronic Graft-Versus-Host Disease Trial
DailyMed - NIKTIMVO- axatilimab-csfr injection
Incyte and Syndax Receives US FDA Approval for Niktimvo (axatilimab ...
FDA Approves Axatilimab-csfr for Chronic Graft-vs-Host Disease
Frontiers | The multikinase inhibitor axitinib in the treatment of ...
ASTCT Applauds FDA Approval of Axatilimab-Csfr for the Treatment of ...
US FDA Announces Priority Review For Chronic GVHD Treatment
Pharmacist’s Application to Practice: Axatilimab-csfr | HOPA
Axatilimab, First-in-Class Treatment for Chronic GVHD, Shows Strong ...
10-K
FDA Approves Axatilimab-csfr 9 mg and 22 mg Vial Sizes for cGVHD ...
Axatilimab: A New Frontier for Steroid-Refractory Chronic GVHD ...
FDA Approves Niktimvo (axatilimab-csfr) for the Treatment of Chronic ...
Rapid Readouts: Safety, Tolerability, and Efficacy of Axatilimab, a CSF ...
FDA gives green light for axatilimab-csfr as treatment for chronic ...
NIKTIMVO™ (axatilimab-csfr) - chronic graft-versus-host disease (cGVHD ...
The Effects of Prior Lines of Therapy on Clinical Outcomes for Patients ...
Axatilimab: First Approval | Drugs
23 August 2024: FDA approves Niktimvo (axatilimab-csfr) to treat ...
Axatilimab: First Approval | Drugs | Springer Nature Link
Niktimvo (axatilimab-csfr): Uses, Side Effects, Interactions, Pictures ...
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab ...
FDA Approves Axatilimab-csfr (CSF1R-Blocking Antibody) to Treat Chronic ...
Descubriendo el Potencial de Axatilimab: Avances Claves en el ...
Skin Responses Using Modified Criteria Among Patients with Sclerotic ...
axatilamab (SNDX-6352) / Syndax Pharma, UCB, Incyte
Dynamics of Infusion-Related Reactions in Patients Treated with ...
Axatilimab-Csfr | Chronic Graft-Versus-Host Disease
FDA Approves Axatilimab-csfr (Niktimvo) for Chronic Graft-Versus-Host ...
